下载后可任意编辑齐拉西酮在氯氮平所致体重增加中的应用齐拉西酮在氯氮平所致体重增加中的应用 林晓鸣 余敏 梁晓敏 [摘要]目的 探讨齐拉西酮在氯氮平所致体重增加中的应用效果。方法 选取 20XX 年 1 月～20XX 年 1 月我院收治的 80 例精神分裂症患者作为讨论对象，根据随机数字表法分为讨论组（40 例）与对比组（40 例），讨论组采纳氯氮平联合齐拉西酮治疗，对比组采纳氯氮平单一治疗。比较两组的体重和体重指数，并采纳阳性和阴性症状量表（PANSS）及不良反应量表（TESS）分别评定临床疗效和不良反应。结果 经治疗 12 周后，两组脱落率比较，差异无统计学意义（P>0.05）。经治疗 12 周后，讨论组患者的体重、体重指数和 PANSS 总分低于对比组，差异有统计学差异（P0.05）。结论 齐拉西酮可降低氯氮平所致精神分裂症患者体重，且安全性好，但进一步临床推广应用需循证医学支持。 [关键词]齐拉西酮;精神分裂症;氯氮平;体重;体重指数 [Abstract] Objective To investigate the application of Ziprasidone for weight gain induced by Clozapine in patients with schizophrenia. Methods A total of 80 patients with chronic schizophrenia were recruited from January 20XX to January 20XX in our hospital. Based on the random number table method ， they were assigned to the study group （n=40）and the control group （n=40）. The study group was treated with Ziprasidone combined with Clozapine， and the control group was treated with Clozapine. Body weight and body mass index were assessed between the two groups. Similarly ， clinical efficacy and adverse drug reactions were assessed by using positive and negative syndrome scale （PANSS） and treatment emergent symptom scale （ TESS ） ， respectively. Results After 12 weeks of treatment， there was no significant difference in the rate of discontinuation between the two groups （P>0.05）. After 1下载后可任意编辑12 weeks of treatment， the body weight and body mass index of the patients and the total score of PANSS in t...
